KM

Kumkum Mittal

Active Director Director DIN 09344170
DIN 09344170 First appointment Oct 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2021
Shareholding value •••• Premium profile

About Kumkum Mittal

Data last updated:

Kumkum Mittal is a Director at Perfocon Pharma Private Limited (since 2021). The company operates in Pharma. Perfocon Pharma Private Limited reported revenue of ₹6.24 Cr (FY 2025).

DIN 09344170
Primary Designation Director
Industry Pharma
First Appointment 04 Oct 2021
Oldest Company Age 7 yrs
Largest company Perfocon Pharma Private Limited · ₹6.24 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Perfocon Pharma Private Limited U51909UP2018PTC110035
Director04 Oct 20212018₹6.24 Cr (FY 2025)Active

Board colleagues of Kumkum Mittal

Directorship timeline

Open interactive timeline →
Perfocon Pharma Private Limited
Premium access

Shareholding and investment profile for Kumkum Mittal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kumkum Mittal

Kumkum Mittal currently holds 1 directorship: Perfocon Pharma Private Limited (Director, since 04 Oct 2021, revenue ₹6.24 Cr (FY 2025)).

Kumkum Mittal was first appointed on 04 Oct 2021 as Director at Perfocon Pharma Private Limited.

The current boards of Kumkum Mittal's companies include Anjul Agarwal (Perfocon Pharma Private Limited), Suchita Mittal (Perfocon Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available